

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 23, 2022

NextCure, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation)

001-38905
(Commission File Number)

47-5231247
(IRS Employer Identification No.)

9000 Virginia Manor Road, Suite 200
Beltsville, Maryland
(Address of principal
executive offices)

20705
(Zip Code)

Registrant's telephone number, including area code: **(240) 399-4900**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	NXTC	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 23, 2022, NextCure, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”). Set forth below are the matters voted upon at the Annual Meeting and the final voting results for each matter as certified by the inspector of election.

Proposal No. 1: Election of Class III Directors

The Company’s stockholders elected David Kabakoff, Ph.D, Michael Richman and Stephen W. Webster as Class III members of the Company’s Board of Directors (the “Board”), each to serve for a three-year term expiring at the Company’s 2025 Annual Meeting of Stockholders, or until such director’s earlier death, resignation, or removal from the Board. The results of the votes were as follows:

Nominee	For	Against	Abstain	Broker Non-Votes
David Kabakoff, Ph. D	11,548,824	1,187,004	245,392	4,783,701
Michael Richman	11,609,302	1,124,238	247,680	4,783,701
Stephen W. Webster	11,530,304	1,202,184	248,732	4,783,701

Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The results of the vote were as follows:

For	Against	Abstain	Broker Non-Votes
17,631,748	53,399	79,774	-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 23, 2022

NEXTCURE, INC.

By: /s/ Steven P. Cobourn

Name: Steven P. Cobourn

Title: Chief Financial Officer
